Jacksonville, FL - Data from a pharmacodynamic study suggests that acute coronary syndrome (ACS) patients can be safely switched from maintenance clopidogrel (Plavix, Bristol-Myers ...

NEW ORLEANS, LA—Ticagrelor did not prove to be noninferior to prasugrel as part of dual antiplatelet therapy (DAPT) following PCI in patients with diabetes and multivessel coronary disease in the ...

Prasugrel-based dual antiplatelet therapy is associated with increased major bleeding after stent implantation for high-risk patients with stable coronary artery disease, according to a secondary ...

Please provide your email address to receive an email when new articles are posted on . In patients with diabetes and multivessel coronary artery disease who had PCI, ticagrelor was not noninferior to ...

When choosing a P2Y12 inhibitor to use in combination with aspirin in patients with diabetes undergoing percutaneous coronary intervention (PCI) for multivessel disease, prasugrel may be preferable to ...